10 / 15
Page 50
Notes:
conferenceseries
.com
Volume 7, Issue 5 (Suppl)
J Gastrointest Dig Syst, an open access journal
ISSN:2161-069X
Gastroenterology 2017
November 13-14, 2017
November 13-14, 2017 | Las Vegas, USA
13
th
International Conference on
Clinical Gastroenterology, Hepatology and Endoscopy
Extremely high levels of CA19-9 levels detected innewly diagnosedpatient withpancreatic adenocarcinoma
F Khemani
and
S Eswaran
Rush University Medical Center, USA
P
ancreatic cancer has one of the highest mortality rates of any cancer with a poor prognosis and a five-year survival rate of 6%. CA
19-9 is the most well studied pancreatic cancer marker and is an important tool for diagnosis, prognosis and monitoring disease
activity. We report a case study of a patient diagnosed with metastatic pancreatic cancer with exceedingly high levels of CA 19-9 not
previously seen, to the best of our knowledge. A 72-year-old Hispanic male with a past medical history of colonic tubular adenoma
and H. pylori, was referred to the gastroenterology clinic for rapid weight loss over two months, loss of appetite and abdominal pain.
The laboratory work-up was significant for elevated liver enzymes, ALP 601, CA 19-9 281431, CEA 6.2. A CT scan showed numerous
hypodense hepatic lesions, a hypodense pancreatic mass, and scattered sclerotic lesion of the right pelvis. A liver biopsy revealed
adenocarcinoma consistent with pancreatobiliary primary, positive for cytokeratin 7. Given the metastatic picture, chemotherapy
was suggested, however the patient elected to transfer to a different institution. CA 19-9 is produced by human pancreatic and biliary
ductular cells. There is growing evidence demonstrating that high levels of CA 19-9 are associated with the severity of pancreatic
malignancy. The high levels detected in our patient indicated advanced disease and poor prognosis. However, no reported cases of
CA 19-9 levels greater than 200,000 have been reported in patients with pancreatic cancer and the precise mechanism of enormous
elevation of CA 19-9 remains unclear.
Biography
F Khemani has completed his MD from Medical University of the Americas and currently employed as Research Fellow at Rush University Medical Center in the Hepatology
Department.
Fahad_Khemani@rush.eduF Khemani et al., J Gastrointest Dig Syst 2017, 7:5 (Suppl)
DOI: 10.4172/2161-069X-C1-056